Companies: 10,795·Total market cap: $144.5T
Drug Free Solution, Inc.

Drug Free Solution, Inc.

DSOLOTCHealthcare● Active
$0.00
+$0.00(+0.00%)
Market Cap$88891
P/E Ratio
52W High$0.1
52W Low$0.0002

Drug Free Solution, Inc. (DSOL) PE Ratio — Current & Historical Data

Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.

dsol · pe ratio · data through May 31, 2025

Core PE Ratio Metrics

Trailing 12 months · TTM

The price-to-earnings (P/E) ratio for Drug Free Solution, Inc. (DSOL) measures how much investors pay for each dollar of the company's trailing earnings. DSOL's current PE ratio of N/A is calculated by dividing its stock price of $0.00 by its TTM earnings per share of -$0.00.

N/A
P/E Ratio (TTM)N/A — Company is not profitable (TTM)

Source: FMP · /ratios-ttm · /analyst-estimates · 2025-05-31

Forward P/E
N/A
EPS (TTM)
-$0.00
TTM · diluted EPS
PEG Ratio
-0.08
Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Drug Free Solution, Inc. SEC 10-K & 10-Q filings · US GAAPUpdated: 2026-06-09

PE Ratio History

2013 – 2025 · Annual
PE Ratio (TTM)
EPS (Annual)

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)

PE Ratio vs Peers

Medical - Healthcare Information Services · 6 peers · Annual PE
CompanyMarket CapPE (Annual)vs AvgEPS (TTM)
Drug Free Solution, Inc.
Drug Free Solution, Inc.You
DSOL
$0MN/A-$0.00
Alternate Health Corp.
Alternate Health Corp.
AHGIF
$0MN/A-$0.44
The Cannabist Company Holdings Inc.
The Cannabist Company Holdings Inc.
CBSTF
$14MN/A-$0.23
Cynata Therapeutics Limited
Cynata Therapeutics Limited
CYYNF
$37MN/A-$0.05
iAnthus Capital Holdings, Inc.
iAnthus Capital Holdings, Inc.
ITHUF
$32MN/A-$0.01
Leef Brands Inc.
Leef Brands Inc.
LEEEF
$34MN/A-$0.10
Medical Developments International Limited
Medical Developments International Limited
MDDVF
$34M608.90x$0.00

* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio

Annual PE Ratio History

Showing 8 of 8 years
Fiscal Year EndPE RatioEPS (TTM)YoY ChangePE vs Max
2025-05-31Latest
FY2025
$-0.00
2024-05-31
FY2024
$-0.00
2023-05-31
FY2023
$-0.00
2020-05-31
FY2020
$-0.00
2019-05-31
FY2019
$-0.01
2018-05-31
FY2018
$-0.00
2017-05-31
FY2017
$-0.00
2013-05-31
FY2013
$-8.93

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API

About PE Ratio & Methodology

The price-to-earnings (P/E) ratio for Drug Free Solution, Inc. (DSOL) measures how much investors pay for each dollar of the company's trailing earnings. DSOL's current PE ratio of N/A is calculated by dividing its stock price of $0.00 by its TTM earnings per share of -$0.00.

PE Ratio = Stock Price ÷ EPS (TTM)
= $0.00 ÷ -$0.00 = N/A
TTMTrailing Twelve Months — sum of the most recent 4 quarterly EPS figures
Forward PEStock price ÷ analyst consensus EPS estimate for the next fiscal year
PEGPE ÷ earnings growth rate — values below 1.0 suggest growth may justify the premium
Figures tie to SEC 10-K/10-Q and FMP ratio endpoints where noted.

Frequently asked questions

DSOL pe ratio · 6 questions

DSOL's current PE ratio is N/A as of 2026-06-09, based on a stock price of $0.00 and TTM EPS of -$0.00. Data sourced from Financial Modeling Prep via DSOL's SEC 10-K and 10-Q filings.

DSOL PE ratioWhat is DSOL PE ratioCurrent PE ratio of DSOLDSOL PE ratio today

Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Drug Free Solution, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09